TOVX

Theriva Biologics, Inc. (TOVX) | Rumor.io

Theriva Biologics

TOVX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,530

Bullish sentiment (50-day avg)92%

Price to earnings ratio0.15

Market capitalization10.1M

Earnings per share1.44

Dividend yield (TTM)2.8K%

Revenue (annual)0

Net income (annual)-23.7M

Social

What share of all stock conversation is about TOVX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 19

Theriva Biologics, Inc. ($TOVX) is expected to break out, with some predicting it will be the next big move.
$TOVX is being watched closely by investors, with some anticipating a significant increase in its value.
The .236 level is seen as a key target for $TOVX.

Generated by AI

Sentiment

Of the messages about TOVX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +7.94	86.79% +5.01
Bearish	—	—	0% -7.94	13.21% -5.01

Bullish· Aug 19

TOVX is poised for a breakout, according to market observers.
Theriva Biologics, Inc.'s stock is expected to continue its upward trend.
The company's strong fundamentals make it an attractive investment opportunity.

Bearish· Jun 11

$TOVX is experiencing a 10% loss.
The company's Phase 1 results are being dismissed as "sugar pills" with no potential for success.
The stock's low price and dilution of shareholder value make it a poor investment.

Generated by AI

Topics

Of the messages about TOVX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	89.29%	35.46%
Technical Analysis	—	—	0%	26.59%
Analysts	—	—	3.57%	18.37%
Macro	—	—	0%	18.96%
Controversies	—	—	7.14%	0.59%
Earnings	—	—	0%	0.04%

Announcements· Jun 11

Theriva Biologics, Inc. announced the publication of clinical, translational results from VCN-01's Phase 1 clinical trial in Head and Neck Squamous Cell Carcinoma in Clinical Cancer Research journal.
The trial demonstrated the ability of VCN-01 to resensitize tumors from heavily pretreated patients to the immune checkpoint inhibitor durvalumab, with pharmacokinetic, tissue biopsy, radiomic, and transcriptomic results supporting the VCN-01 stroma-degrading mode-of-action.
The results showed prolonged overall survival (up to 17.3 months) and pharmacokinetic and biomarker changes consistent with the VCN-01 stroma-degrading mode-of-action, with 20 patients in the trial.

Technical Analysis· Apr 20

$TOVX has broken out with high volume, RSI hitting new highs, and a strong momentum wave.
The stock needs to break the downtrend and VWAP at 0.47 to continue its upward momentum.
The next potential resistance levels for $TOVX are 0.50, 0.62, 0.75, and 0.95, based on the identified technical analysis.

Generated by AI

Community

Of the messages about TOVX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	66.67%	40.43%	42.24%
Newcomers	—	33.33%	59.57%	57.76%

Regulars· Apr 20

The company is in a strong uptrend, with some participants expecting continuation into the next couple of days.
There are multiple entries in the stock that have paid off significantly, with one participant reporting a +40% gain and another a +135% gain.
The stock is breaking out, with one participant noting that the chart "couldn't be nicer this early in PM".

Newcomers· Aug 19

Many newcomers are expecting a breakout for Theriva Biologics, Inc. ($TOVX), with some comparing it to other assets like $GDC and $BTCT.
Some users are speculating that $TOVX is next in line for a significant price increase, with one user using a "ready to break out" phrase.
Newcomers are also discussing technical analysis, with one user referencing a specific trading level (".236 zends itttt").

Generated by AI

– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients – – Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 – ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing ther

1mo agoYahoo Finance UK

Theriva Biologics: Q2 Earnings Snapshot

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

1mo agoYahoo Finance

Theriva doses first patient in VCN-01 pancreatic cancer trial

1mo agoInvesting.com

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

- VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in metastatic pancreatic ductal adenocarcinoma (PDAC) - - Study builds on positive clinical data from the VIRAGE Phase 2b study and feedback from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) recognizing the potential of repeated VCN-01 dosing to provide clinical benefit - ROCKVILLE, Md., Aug. 06, 2026 (GLOBE NEWSWIRE)

1mo agoYahoo! Finance Canada

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

- VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial - - Study builds on positive clinical data from the recent VIRAGE study and feedback from the EMA and FDA recognizing the potential of repeated VCN-01 dosing to provide clinical benefit - ROCKVILLE, Md., July 07, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat can

2mo agoYahoo Finance

Theriva Biologics receives approval to start VIRAGE2 cancer trial

2mo agoInvesting.com

Also Discussed

Investors talking about TOVX also mention

#	Name	Attention
1	Alaunos Therapeutics Inc.TCRT	0%new
2	Precigen Inc.PGEN	0%+0
3	Allied Gaming & Entertainment Inc.AGAE	0%0
4	Scienture Holdings, Inc.SCNX	0%0
5	Virax Biolabs Group Ltd.VRAX	0%+0
6	Palisade Bio Inc.PALI	0%new
7	Gen Digital Inc.GEN	0%+0
8	Linkers Industries LimitedLNKS	0%0
9	TNL Mediagene Ordinary SharesTNMG	0%new
10	Plus Therapeutics IncPSTV	0%0

Theriva Biologics, Inc.

Healthcare
Biotechnology

Theriva Biologics Inc. is a clinical-stage biotechnology company focused on developing therapeutics for cancer and related diseases with significant unmet medical needs. The company’s current pipeline centers on oncolytic adenovirus technology, including VCN-01, an investigational program designed to selectively attack tumor cells and support the delivery of co-administered cancer therapies. Theriva Biologics is also advancing microbiome-related candidates such as SYN-004 and SYN-020, which are intended to help preserve the gut microbiome during antibiotic treatment and address complications linked to microbiome disruption. Its programs span oncology, infectious disease prevention, and gastrointestinal health, reflecting a diversified approach to therapeutic development. Based in Rockville, Maryland, Theriva Biologics operates as a research-driven developer of novel treatment platforms for areas where current options remain limited.

Website

Location

9605 Medical Center Drive

Rockville, MD, 20850

United States

Social

What share of all stock conversation is about TOVX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 19

Theriva Biologics, Inc. ($TOVX) is expected to break out, with some predicting it will be the next big move.
$TOVX is being watched closely by investors, with some anticipating a significant increase in its value.
The .236 level is seen as a key target for $TOVX.

Generated by AI

Sentiment

Of the messages about TOVX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +7.94	86.79% +5.01
Bearish	—	—	0% -7.94	13.21% -5.01

Bullish· Aug 19

TOVX is poised for a breakout, according to market observers.
Theriva Biologics, Inc.'s stock is expected to continue its upward trend.
The company's strong fundamentals make it an attractive investment opportunity.

Bearish· Jun 11

$TOVX is experiencing a 10% loss.
The company's Phase 1 results are being dismissed as "sugar pills" with no potential for success.
The stock's low price and dilution of shareholder value make it a poor investment.

Generated by AI

Topics

Of the messages about TOVX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	89.29%	35.46%
Technical Analysis	—	—	0%	26.59%
Analysts	—	—	3.57%	18.37%
Macro	—	—	0%	18.96%
Controversies	—	—	7.14%	0.59%
Earnings	—	—	0%	0.04%

Announcements· Jun 11

Theriva Biologics, Inc. announced the publication of clinical, translational results from VCN-01's Phase 1 clinical trial in Head and Neck Squamous Cell Carcinoma in Clinical Cancer Research journal.
The trial demonstrated the ability of VCN-01 to resensitize tumors from heavily pretreated patients to the immune checkpoint inhibitor durvalumab, with pharmacokinetic, tissue biopsy, radiomic, and transcriptomic results supporting the VCN-01 stroma-degrading mode-of-action.
The results showed prolonged overall survival (up to 17.3 months) and pharmacokinetic and biomarker changes consistent with the VCN-01 stroma-degrading mode-of-action, with 20 patients in the trial.

Technical Analysis· Apr 20

$TOVX has broken out with high volume, RSI hitting new highs, and a strong momentum wave.
The stock needs to break the downtrend and VWAP at 0.47 to continue its upward momentum.
The next potential resistance levels for $TOVX are 0.50, 0.62, 0.75, and 0.95, based on the identified technical analysis.

Generated by AI

Community

Of the messages about TOVX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	66.67%	40.43%	42.24%
Newcomers	—	33.33%	59.57%	57.76%

Regulars· Apr 20

The company is in a strong uptrend, with some participants expecting continuation into the next couple of days.
There are multiple entries in the stock that have paid off significantly, with one participant reporting a +40% gain and another a +135% gain.
The stock is breaking out, with one participant noting that the chart "couldn't be nicer this early in PM".

Newcomers· Aug 19

Many newcomers are expecting a breakout for Theriva Biologics, Inc. ($TOVX), with some comparing it to other assets like $GDC and $BTCT.
Some users are speculating that $TOVX is next in line for a significant price increase, with one user using a "ready to break out" phrase.
Newcomers are also discussing technical analysis, with one user referencing a specific trading level (".236 zends itttt").

Generated by AI

Theriva Biologics

Social

Aug 19

Bullish· Aug 19

Bearish· Jun 11

Announcements· Jun 11

Technical Analysis· Apr 20

Regulars· Apr 20

Newcomers· Aug 19

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Theriva Biologics: Q2 Earnings Snapshot

Theriva doses first patient in VCN-01 pancreatic cancer trial

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Theriva Biologics receives approval to start VIRAGE2 cancer trial

Also Discussed

Theriva Biologics, Inc.

Company Information

Location

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Theriva Biologics: Q2 Earnings Snapshot

Theriva doses first patient in VCN-01 pancreatic cancer trial

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Theriva Biologics receives approval to start VIRAGE2 cancer trial

Also Discussed

Social

Aug 19

Bullish· Aug 19

Bearish· Jun 11

Announcements· Jun 11

Technical Analysis· Apr 20

Regulars· Apr 20

Newcomers· Aug 19